Bumpy ride for BTG and Astra after trials failure
AstraZeneca and BTG yesterday axed plans to develop a new drug to treat severe blood poisoning after it failed medical trials.
Stage II trials comparing doses of the duo's CytoFab treatment with placebo drugs in patients with severe septicaemia or septic shock "did not show any significant improvements versus the placebo", the firms admitted.
As a result, the drug has been shelved, leaving BTG, led by Louise Makin, with a £28m charge for this financial year. Its shares were knocked back in early trading, although by the end of the day the stock had recovered. AstraZeneca shares lost 61p to 3015p but most of that was because its dividend was being paid out yesterday.
- 1 Stem cells that can kill cancer have been engineered by scientists
- 2 Ricky Gervais and Dame Judi Dench back campaign to stop Thailand dog meat trade
- 3 Russell Brand says he will 'probably' give up acting to focus on his revolution
- 4 Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
- 5 Queen's first tweet: Reply telling Her Majesty to 'f*** off' broadcast on BBC News
Stem cells that can kill cancer have been engineered by scientists
Ottawa shooting: 'Sergeant-at-arms shot suspect at point-blank range after diving around pillar'
Russell Brand says he will 'probably' give up acting to focus on his revolution
McKamey Manor: This 'extreme' haunted house is the stuff of nightmares
Jack Bruce dead: Cream bass player dies of liver disease aged 71
Of course, teenage girls need role models – but not like beauty vlogger Zoella
Support for EU membership 'at highest level since 1991' with most Brits wanting to stay 'in'
Tony Blair 'says Ed Miliband will lose 2015 general election'
Thousands with degenerative conditions classified as 'fit to work in future' – despite no possibility of improvement
Putin: The US is to blame for almost all the world's major conflicts
Attacks on 'Ukip Calypso' show how skewed people’s priorities are
iJobs Money & Business
£60000 per annum: Ashdown Group: Compensation and Benefits Manager - Compensat...
£30000 - £35000 Per Annum plus excellent benefits: Clearwater People Solutions...
£24000 - £28000 per annum + bonus & benefits: Ashdown Group: IT Business Syste...
£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...